DALLAS and FORT WORTH, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a
pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin
Garg, Ph.D., president and chief executive officer will present a business overview and update at the following two upcoming
September conferences:
- Wells Fargo 2017 Healthcare Conference at 3:00 p.m. E.T. on Wednesday, September 6, 2017 in Boston, MA
- Cantor Fitzgerald Global Healthcare Conference at 8:35 a.m. E.T. on Tuesday, September 26, 2017 in New York, NY
A live audio webcast of both events will be available on the Investor Relations page of the company’s website at
http://investors.neostx.com/. An archived replay of the webcast will be available for 30 days
after the live event concludes.
Neos management will also be available for one-on-one meetings at the Mizuho Biotechnology Conference 2017 on
Tuesday, September 19, 2017 in Boston, MA.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT®, indicated for the
treatment of ADHD in patients 6 years of age and older, and Cotempla XR-ODTTM, indicated for the treatment of ADHD in
patients 6 to 17 years old, are the first approved products using the Company’s extended-release (XR)-orally disintegrating tablet
(ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the
U.S. Food and Drug Administration for one other branded product candidate that is an XR medication in oral suspension dosage form.
In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral
suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a
cold.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 reisenstadt@neostx.com Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 sarah@sternir.com
